

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Abstract

Objective. Goodman and Gilman’s *The Pharmacological Basis of Therapeutics* (_{GG}PBT) has been a cornerstone in the education of pharmacists, physicians, and pharmacologists for decades. The objectives of this report were to describe and evaluate the 13th edition of _{GG}PBT including: 1) author characteristics; 2) recency of citations; 3) conflict of interest (CoI) disclosure, and 4) expert evaluation of chapters.

Methods. Contributors’ (N = 115) sex, professional degrees, and presence of undisclosed potential CoI as reported by the Center for Medicare and Medicaid’s Open Payments (2013 to 2017) were examined. Year of publication of citations were extracted relative to comparison textbooks (Katzung’s *Basic and Clinical Pharmacology* (_{Kat}BCP), and DiPiro’s *Pharmacotherapy: A Pathophysiologic Approach* (_{Dip}PAPA). Content experts in pharmacy and pharmacology education provided chapter reviews.

Results. The percent of _{GG}PBT contributors that were female (20.9%) was equivalent to those in _{Kat}BCP (17.0%). Citations in _{GG}PBT (11.5 ± 0.2 years) were significantly older than those in _{Kat}BCP (10.4 ± 0.2) and _{Dip}PAPA (9.1 ± 0.1 , $p < .0001$). Contributors to _{GG}PBT received three million in undisclosed remuneration from pharmaceutical companies (Maximum author = \$743,718). In contrast, _{Dip}PAPA made CoI information available. However, self-reported disclosures were not uniformly congruent with Open Payments reported data. Reviewers noted several strengths but also some areas for improvement.

Conclusion: _{GG}PBT will continue to be an important component of the biomedical curriculum. Areas of improvement include more diverse authorship, improved conflict of interest transparency, and greater inclusion of more recent citations.

Keywords: education, ethics, pharmacy, pharmacology, textbook

50 INTRODUCTION

51 Educator and pharmacologist Louis S. Goodman (1906 – 2000) completed his undergraduate
52 degree at Reed College and his MD at the University of Oregon Medical School in Portland, Oregon.
53 Goodman and Alfred Gilman, his colleague and collaborator on nitrogen mustard investigations,
54 published the first edition of *Pharmacological Basis of Therapeutics* (GGPBT) in 1941. Louis’s son Alfred
55 G (Goodman) Gilman (1941- 2015) received a Nobel prize for his work on signal transduction and served
56 in various editorial capacities for the 5th to 10th editions. The first reviewer was “delirious in his appraisal
57 of the book” and anticipated it would become the standard text in pharmacology.¹ The eighteen hundred
58 page 2nd edition published in 1956 was referred to as encyclopedic and indispensable.² A reviewer noted
59 that “all other related books seem to pale by comparison”.³ An evaluation of the 6th edition published in
60 1980 commended the extensive bibliography but was more measured and noted that although “this book
61 is recommended to all those who prescribe drugs”, GGPBT had become “too large to be used by medical
62 students as a routine textbook”.⁴ Hastings and Long referred to GGPBT as the “blue bible of
63 pharmacology” and the “gold standard”.⁵ Rosenberg warmly commended this reference for dentistry and
64 anesthesiology.⁶ However, despite the book’s esteemed and authoritative status, a subsequent reviewer
65 alluded to one chapter where the text had “barely kept up” with the rapid pace of new therapeutic
66 developments. Casavant also noted the omission of twenty of twenty-six newly approved medications in
67 the 10th edition⁷. The paucity of female authors and absence of potential conflict of interest (CoI)
68 disclosure were concerns expressed about the 12th edition published in 2012.⁸

69 An under-representation of females as authors has been identified in different fields and types of
70 publications. Female first authorship in six, high-impact, general medical journals increased from 27% in
71 1994 to 37% in 2014.⁹ Senior authorship by women in cardiology journals doubled from 6% in 1996 to
72 12% in 2016.¹⁰ Textbook authorship, which often involves large teams, is highly variable and ranged
73 from half (53%) female for an advanced pharmacy textbook, the 2014 9th edition of DiPiro’s

74 *Pharmacotherapy: A Pathophysiological Approach* (DiPAPA),¹¹ to one out of seven (14%) in Yagiela's
75 *Pharmacology and Therapeutics for Dentistry*.^{8,12}

76 Conflicts of interest (CoIs) were defined as “a set of circumstances that creates a risk that
77 professional judgment or actions regarding a primary interest will be unduly influenced by a secondary
78 interest”.¹³ The transparency of conflicts of interest has become increasingly ubiquitous for primary
79 sources¹⁴ including clinical trials,¹⁵ undergraduate medical education,¹⁶ continuing medical education,¹⁷
80 point of care computerized sources,¹⁸ meta-analyses,¹⁹ and clinical practice guidelines.²⁰ The US
81 Physician Payments Sunshine Act of 2010 required that all compensation (\geq \$10) to doctors of medicine,
82 osteopathy, dentistry, dental surgery, podiatry, optometry, and chiropractic medicine (i.e. PharmDs, PhDs,
83 PAs, and NPs were not covered although this subsequently changed for PAs and NPs) by manufacturers
84 of drugs and medical devices be reported to the Centers for Medicare and Medicaid Services (CMS) and
85 made available on its public website. Disclosure of conflicts of interest was provided in the preface to a
86 psychopharmacology textbook²¹ and in DiPiro's *Pharmacotherapy: A Pathophysiological Approach* but
87 this practice is currently uncommon. The database, ProPublica's Dollars for Docs (PDD), originally
88 covered only fifteen pharmaceutical companies. Using the first generation of this database, we found that
89 authors and editors of four biomedical textbooks had received \$2.4 million, primarily for speaking and
90 consulting, which was undisclosed to readers. One-quarter of the contributors to GG PBT, 12th edition, had
91 an undisclosed patent.⁸

92 Here, we extend upon earlier educational research^{8, 12} by assessing the most recent (2018, 13th
93 edition) of GG PBT. This includes quantitative descriptive measures of author characteristics (education,
94 sex), a citation analysis relative to other pharmacology (KatBCP) and pharmacotherapy (DiPAPA)
95 textbooks and characterizing the presence of potential CoI using more comprehensive databases. Content
96 experts also provided detailed assessments in their specialty areas.

97

98 METHODS

99 *Procedures*. The contributors page of the 13th edition of Goodman and Gilman's *The*
100 *Pharmacological Basis of Therapeutics* (_{GGPBT})²² was consulted to obtain professional degrees of
101 authors and editors (N = 115). Sex was determined by a Google search or consulting the National
102 Provider Identifier ([https://www.cms.gov/Regulations-and-Guidance/Administrative-](https://www.cms.gov/Regulations-and-Guidance/Administrative-Simplification/NationalProvIdentStand/)
103 [Simplification/NationalProvIdentStand/](https://www.cms.gov/Regulations-and-Guidance/Administrative-Simplification/NationalProvIdentStand/)). The presence of CoI was deemed exempt by the Wright Center
104 Institutional Review Board and evaluated with two publically available databases, the Center for
105 Medicare and Medicaid Service's Open Payments (_{CMSOP}) and ProPublica's Dollars for Docs (_{PPDD}).
106 These databases differ slightly with respect to when potential CoI information is made available and to
107 details (e.g. specific companies and products) about disclosures, with ProPublica's Dollars for Docs being
108 updated less frequently but providing greater depth. Payments were obtained for 2013 to 2017. The
109 second generation of _{PPDD} reported on \$9.2 billion in payments from two-thousand companies to nine-
110 hundred thousand physicians. Among _{GGPBT} authors with a US affiliation (N = 109), 42.3% had
111 professional degrees that were covered by the Sunshine Act (i.e. PhDs and PharmDs were not covered).
112 Year of publication of each reference for 72 chapters including the Appendix (N = 3,576) was obtained.
113 The publication year of all citations of Katzung's *Basic and Clinical Pharmacology* (_{KatBCP}, 2018, N =
114 1,777)²³ and _{DipPAPA} (9th ed., 2017, N = 13,389)¹¹ including eChapters were also obtained for
115 comparison.

116 For the narrative reviews, content experts were consulted. Experts included academic
117 pharmacists, physiologists, molecular biologists, a psychiatry resident, a neuroscientist, a neurologist, and
118 a bioinformaticist. Experts were instructed to succinctly provide strengths and limitations and, if
119 applicable, to make comparisons with other textbooks they use. Some provided assessments of a specific
120 chapter, others provided an evaluation of an entire section. Two recent graduates from a Master's in
121 Biomedical Sciences program provided student perspectives. The goal was not to be comprehensive of all
122 71 chapters but instead to provide at least a sampling from most sections.

123 *Data-analysis*. Statistical analysis was completed with Systat, version 13.1 with $p < .05$
124 considered significant. Figures were prepared with GraphPad Prism. Sex of contributors of _{GGPBT} was

125 compared to other pharmacy and biomedical textbooks obtained previously.^{8, 11} Age of references was
126 calculated as the difference between publication year and the copyright year. The similarity between CoI
127 databases was evaluated with a Pearson correlation and t-test. Variability was expressed as the SEM with
128 a $p < .05$ considered statistically significant.

129

130 RESULTS

131 1. Quantitative

132 In Goodman and Gilman's *The Pharmacological Basis of Therapeutics* (_{GG}PBT), there were 115
133 authors, of which 32 contributed to more than one chapter. The highest degree was MD for half of authors
134 (47.0%), PhD for two-fifths (45.2%), and the remainder (7.8%) PharmDs. The preponderance (90.4%) of
135 authors were based in the US.

136 One-fifth (20.9%) of authors were female or 19.0% if including multiple chapter contributions.
137 Female authorship in _{GG}PBT was equivalent to that of Katzung's *Basic and Clinical Pharmacology*
138 (_{Kat}BCP, 17.0%, $p = .52$) but less than Remington's *Science and Practice of Pharmacy* (37.0%, $\chi^2(1) =$
139 8.84, $p \leq .003$) and Koda-Kimble and Young's *Applied Therapeutics* (53.0%, $\chi^2(1) = 8.84$, $p < .001$).

140 Figure 1A shows that references in _{GG}PBT were 12.3% older (11.5 years) than those in _{TK}BCP
141 (10.4, $t(5,321) = 4.42$, $p < .0005$). The DiPiro's *Pharmacotherapy: A Pathophysiological Approach*
142 (_{DiP}PAPA) citations (9.1 years) were also more recent than _{GG}PBT ($t(16,951) = 15.59$, $p < .0001$).

143 Similarly, additional analysis determined that more references were \geq a decade old for _{GG}PBT (49.1%)
144 compared to _{Kat}BCP (44.7%, $\chi^2(1) = 9.20$, $p \leq .002$) or _{DiP}PAPA (34.0%, $\chi^2(1) = 278.21$, $p < .0001$).

145 _{Kat}BCP also differed from _{DiP}PAPA on this measure ($\chi^2(1) = 78.44$, $p < .0001$). Figure 1B depicts
146 reference age by section of _{GG}PBT. The Drugs Affecting Gastrointestinal Function were significantly
147 newer than all other sections. Conversely, Neuropharmacology references were 6.7 years older than
148 Gastrointestinal and also significantly less recent than all other sections. There were some broad
149 similarities between _{GG}PBT and _{Kat}BCP (Figure 1C) with oncology citations being more recent,

150 endocrinology intermediate, and neuroscience the oldest. The gastrointestinal, as well as gynecological,
151 citations were most recent relative to many other sections in $_{DiP}PAPA$ (Figure 1D).

152 The similarity of the conflict of interest databases ProPublica's Dollars for Docs ($_{ppDD}$) and
153 Medicaid Service's Open Payments ($_{CMSOP}$) was examined with two complementary analyses. The
154 correlation between the total received from 2013 to 2016 (i.e. the most recent available in both databases)
155 was high ($r(24) = +0.999, p < .0005$; Supplementary Figure 1). However, the mean amount received was
156 eighteen-hundred dollars higher for $_{CMSOP}$ ($\$82,923 \pm 24,404$) than $_{ppDD}$ ($\$81,105 \pm 24,122$), a non-
157 significant difference ($t(25) = 1.59, p = .13$).

158 Total undisclosed remuneration received by twenty-seven $_{GGPBT}$ authors (57.4% of eligible US
159 based physician-authors, 96.3% male, Minimum = \$23, Maximum = \$743,718) from 2013 to 2017 was
160 \$2.97 million of which almost three-quarters (71.4%) went to the top five authors. The most compensated
161 author received \$493,536 (66.0% of their total) for royalty or licenses and \$250,108 (34.0%) for
162 ownership or investment interest. One of the dermatological pharmacology authors received \$493,536 for
163 ivermectin, a head lice treatment. The psychosis and mania chapter author received \$238,413 for
164 payments related to two atypical antipsychotics. The oncologist author of "Hormones and Related Agents
165 in the Therapy of Cancer" received \$228,493 for five breast cancer agents.

166 Additional analyses were completed on $_{DiP}PAPA$ which provides CoI information. Approximately
167 one out of every twelve contributors (20/233 or 8.6%) self-reported a potential CoI. Among the 35
168 eligible (MD or DO with a US affiliation) authors, 74.3% had a $_{ppDD}$ entry (Min = \$14, Max = \$729,695,
169 total = \$1.8 million). However, some discrepancies were identified. A status epilepticus author whose
170 disclosures were self-reported as "none" received a half-million for anti-epilepsy drugs according to
171 $_{ppDD}$. Two authors who did not report disclosures to $_{DiP}PAPA$ accepted \$70-350 thousand in potentially
172 relevant remuneration from 2013 to 2016 (Supplemental Table 1).

173 *2. Narrative Reviews*

174 Open-ended evaluations were provided on sixteen chapters including representation of seven of
175 the nine sections of Goodman and Gilman’s *The Pharmacological Basis of Therapeutics* (GGPBT).
176 *2.1 General Principles*
177 Chapter 2, “Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, Metabolism, and
178 Elimination” is a comprehensive and thorough explanation and discussion of the basic concepts of
179 pharmacokinetics. The characteristics and processes of absorption, distribution, metabolism, and
180 elimination are reviewed respectively, including an in-depth discussion of the types of transport across
181 membranes and the influence of pH. The first-pass effect as well as the benefits and limitations of various
182 routes of drug administration are also explored. Potentially beneficial additions to the discussion are
183 further examples of specific drugs and their routes of administration, as well as the factors that influence
184 onset of action. There is a brief discussion of rectal administration that could be improved by expanding
185 upon the reasoning behind its incomplete and irregular absorption. Distribution is briefly explored,
186 including a discussion of the differences of distribution among various types of tissues as well as an
187 explanation of protein and tissue binding. While the bone portion of this section focuses mostly on
188 tetracycline antibiotics, an introduction to the pathophysiologic changes in bone that make distribution
189 difficult overall would be helpful. The next section on metabolism is a simplistic but comprehensive
190 explanation of phase one and two reactions, as well as first and zero-order kinetics. A potentially
191 beneficial supplement to this section could be to include examples of when products of metabolism make
192 the drug more toxic (eg. acetaminophen toxicity). The excretion section focuses primarily on renal
193 excretion but also includes that by other routes. Learning is aided by highly beneficial figures that depict
194 renal drug handling and a helpful visual of the afferent and efferent arterioles. A recommendation for
195 improvement is to move the discussion of drugs in breast milk to the distribution section. While placental
196 transfer is discussed in the distribution section, breast milk distribution and potential for ion trapping is
197 not. Tissue distribution is more relevant than elimination when discussing drugs in breast milk. The final
198 section discusses clinical pharmacokinetics and the “four most important parameters governing drug
199 disposition.” While this section is extensive and includes strong drug examples to explain clinical

200 pharmacokinetics, it could be confusing to the reader that components of “clinical pharmacokinetics” are
201 separated from ADME. It may be beneficial to integrate this section into earlier content. Some examples
202 include moving the discussion of extent and rate of absorption under absorption, clearance under
203 excretion, and volume of distribution under distribution. There is a helpful explanation of maintenance
204 and loading doses, therapeutic window, and dosing intervals along with drug examples with each.
205 However, the explanation of therapeutic drug monitoring is somewhat limited and potentially too
206 generalized. Additional examples of therapeutic drug monitoring (for example, a comparison of
207 therapeutic drug monitoring used for vancomycin, aminoglycosides, and warfarin) would be beneficial to
208 the reader in order to understand the parameters that influence different timing and results of monitoring.

209 Chapter 3, “Pharmacodynamics: The Molecular Mechanisms of Drug Action” includes a
210 comprehensive and highly detailed discussion of three primary areas of pharmacodynamics including
211 basic concepts, mechanisms of drug action, and signaling pathways. The first section provides a detailed
212 explanation of different receptor types as well as a short discussion of the increased development of
213 biologic agents. The definitions of agonists, antagonists, and their subtypes are provided. A useful
214 addition to this section would be drug examples of agonists, antagonists, and their subtypes in order to
215 illustrate these concepts further. Specificity of drug receptors and tachyphylaxis are explored, followed by
216 a detailed explanation of affinity, efficacy, and potency. Graphs and mathematical models are used to
217 elaborate upon these concepts. Individual and population pharmacodynamics as well as factors that affect
218 the variability of drug dosing are included. There is also a useful section that expands on the individual
219 patient characteristics that contribute to variability of dosing. There is a section on drug interactions, but it
220 does not mention the effect of CYP enzymes on drug interactions. While this is typically categorized in
221 pharmacokinetics, it may be beneficial to mention their substantial effects on drug levels here. The
222 following section explores the mechanisms of drug action, and expands upon the effects of drugs on
223 ligands, extracellular responses, intracellular pathways, and ions. The mechanisms of anti-infective drugs
224 are also reviewed, which can potentially be eliminated in the overall discussion, or converted to an
225 example instead. There is a helpful review of the structure and function of specific receptor types

226 including second messenger systems and other signaling pathways. Tachyphylaxis and desensitization are
227 discussed again here and could be more beneficial if the discussions on this topic were condensed to one
228 area of the chapter. The chapter ends with an extensively detailed exploration of diseases associated with
229 transcription and translation along with the pharmacotherapies that treat them. Considering that this is an
230 introductory chapter on pharmacodynamics, it may be more useful for this information to be included at a
231 later point in the book. It may be advantageous to consider narrowing this topic to only basic
232 pharmacodynamic concepts.

233 The General Principles section further includes Chapter 7, “Pharmacogenetics”, which provides
234 an overview of the terminology and principles that describe the genetic variations that contribute to drug
235 response phenotypes. A description of the applications of individual genotyping data to inform clinical
236 decisions is provided. Different types of genetic variations which can affect drug response phenotypes are
237 outlined. Each type of genetic variation is linked to a description regarding a change in biological
238 function, which in turn is linked to the phenotype. Emphasis is thereby placed on interpreting the genetic
239 variations in terms of the anticipated functional consequences.

240 As a possible improvement, a further systematic categorization of the linkages between genetic
241 variations and drug response phenotypes may be provided. Consider the categorizations of the linkages
242 given by Katsila et al.³³ The linkages are described in terms of the overall genetic category (poor
243 metabolizer, extensive metabolizer, therapeutic target etc.), the functional effect, the possible phenotype
244 associated with an active drug, and the possible phenotype associated if a pro-drug. Such categorization
245 may help the reader to gain better understanding of apparent themes in the drug response phenotypes. For
246 example, regarding prodrugs, the reader may further expect that an adverse effect would occur in the
247 presence of the drug-activating enzyme that has a relatively high activity.

248 Chapter 7 also advances an understanding of the functional consequences of genetic variations in
249 terms of complete or partial loss of function. A discussion of the increased relative effects of variations at
250 positions with different levels of evolutionary conservation is provided. But in the previous (12th) edition
251 of *Goodman and Gilman’s Pharmacological Basis of Therapeutics* (GGPBT), there was greater

252 delineation of the descriptions of evolutionary conservation versus chemical conservation. It may be
253 helpful to reintroduce that back into the chapter to clarify these important concepts. It may then become
254 clearer that positions in a protein which are highly evolutionary conserved may not allow for an amino
255 acid which is chemically similar if that substituted residue does not enable the protein's specific
256 function.³⁴ In the previous edition, it was more evident that one would need to consider evolutionary
257 conservation and chemical similarity in a somewhat separate light.

258 As a welcome addition to the current edition, there was an informative discussion of the need to
259 consider common versus rare variations of a population when assessing the effects on drug response
260 phenotypes. Discussions are provided regarding how studies are designed to detect common variations
261 and rare variations using candidate gene association studies and genome-wide association studies. It is
262 made apparent that both rare and common variations will need to be considered when predicting the drug
263 response phenotypes. The changes from the 12th edition to the 13th edition with regards to the inclusion
264 of the effects of rare and common variants appear to be due in part to changes the contributing authors.
265 For the 12th edition, the authors were Mary V. Relling and Kathleen Giancomini, while the author for the
266 13th edition is Dan Roden, whose research focus is on characterizing such variations.

267 The number and breadth of the described genetic variations provide the reader with an
268 appreciation how pharmacogenomic information will be used to predict drug response phenotypes and to
269 inform treatment strategies. Consider Table 7-2, entitled "Examples of Genetic Polymorphisms
270 Influencing Drug Response". The presentation of the example drugs provides the reader incentives to
271 understand the related topics which are presented throughout the remainder of the textbook. To aid with
272 that, hyperlinks may be added to Table 7-2 that connect to these topics.

273

274 *2.2 Neuropharmacology*

275 Chapter 15, Drug Therapy of Depression and Anxiety Disorders, includes several strengths.
276 Figure 15.1 illustrates detailed information about the variety of antidepressant mechanisms of action. It
277 provides a list of long term cellular regulatory changes in addition to increasing neurotransmitter "dwell

278 time” in the synapse. The development of ketamine and other approaches as novel antidepressants are
279 well described. Information about pharmacokinetics and CYP action is helpful in a practical way to
280 predict, and avoid, drug interaction. This chapter provides a general summary of the basic treatments for
281 anxiety and depression.

282 As a weakness, chapter 15 does not place very much emphasis on the dopamine or histamine
283 systems/actions in antidepressant effects or depressive etiology. Information about side effects,
284 therapeutic lab, wash-out periods, serotonin syndrome and discontinuation effects are dispersed
285 throughout the text and are not highlighted or emphasized as key pieces of information in designing a
286 treatment strategy. At the beginning of the chapter, depression is immediately categorized into bipolar I
287 and II. It might be more accurate to introduce mood disorders more generally, with an emphasis on
288 depressive symptoms/diagnoses. The authors suggest that there has been limited progress in developing
289 animal models sensitive to antidepressants and anxiolytics. Anxiety is described as “a normal human
290 emotion that serves an adaptive function,” however depression is not.

291 Another concern is that there are places where information is presented without research citations,
292 such as “Anxious patients appear to be particularly prone to severe discontinuation reactions with certain
293 medications such as venlafaxine and paroxetine; therefore, slow-tapering is required.” The chapter does
294 not include information about options for drug-treatment-resistant symptoms or suggestions for
295 combination approaches.²¹ As this is a pharmacology text, that is reasonable. However, it might be helpful
296 to have at least mention of electroconvulsive therapy or transcranial magnetic stimulation, so readers are
297 better informed of other options if drug treatment has been unsuccessful. More specialized textbooks²¹
298 provide at least a nod that the nomenclature for the “Selective” Serotonin Reuptake Uptake Inhibitors is
299 an inaccurate oversimplification.²⁴

300 Chapter 20, “Opioids, analgesia, and pain management” is well organized and includes an
301 emphasis on history, receptor signaling, the pathophysiology of pain, tolerance, withdrawal, and medical
302 chemistry for this important drug class. On rare occasions, there is some unusual content and minor areas
303 for reconsideration. Mentioning that opioids do not bind to sigma receptors, twice, may be less useful for

304 new members of the field. The space devoted to specific opioids does not show any simple relationship
305 with their current use patterns.²⁵ Meperidine and normeperidine, despite concerns with CNS excitation
306 and seizures, are mentioned four times more commonly than the ubiquitous hydrocodone. Tramadol is
307 described, twice, as a “weak opiate agonist”. *Katzung’s Basic and Clinical Pharmacology* (KatBCP) and
308 others have a more nuanced description of the mechanism of action of this agent and the importance of
309 desmethyltramadol.²⁶ The term “addict” or “addicts” are used eight times versus zero for the less
310 stigmatizing “opioid use disorder”.²⁷

311 Chapter 23 “Ethanol” begins with a brief description about the historical use of alcohol in human
312 civilization as well as epidemiologic overview of problems associated with it; this is quite helpful. There
313 also is a practical overview about alcohol content of different beverages as well as information about
314 estimating the blood ethanol concentration in end expiratory alveolar air. Excellent sections with
315 pharmacological properties of methanol and ethanol and its effects are arranged by system. The addition
316 of a Shakespearean quote added emphasis and served as a nice anecdote to illustrate the overview. This is
317 also a good overview about the postulated neurological pathways that are thought to be involved in
318 tolerance and dependence. Descriptions of teratogenicity, genetics, and drug interactions are adequate.
319 Information about treatment of alcohol withdrawal is lacking. No information about choice of drug
320 therapy for withdrawal as well as symptoms triggered therapy protocols (the Clinical Institute Withdrawal
321 Assessment or CIWA protocol for example) for assessment and treatment is provided. This is a surprising
322 omission as alcohol withdrawal is very prevalent and is associated with considerably increased mortality
323 and morbidity as compared to opioid withdrawal.

324 *2.3 Modulation of pulmonary, renal, and cardiovascular function*

325 Chapter 25 has the challenging task of introducing normal renal structure and function as a basis
326 for the mechanistic understanding of drugs that affect the renal excretory function. The chapter does an
327 incredible job in covering clinically relevant renal concepts. However, it is somewhat arbitrary in what is
328 introduced in the chapter’s introduction as “normal” and what is mentioned later, because it is necessary
329 to mention to understand the mechanics of diuretics and other drugs. Some figures and tables are very

330 helpful (e.g., Table 25-1), while others are overloaded and do not add much value (e.g. Figure 25-2).
331 Overall, it is a good chapter, despite the fact that every pathophysiologist will miss some mechanistic
332 understanding of normal (e.g., Mg^{2+} reabsorption) or abnormal processes (e.g. reduction of urinary Ca^{2+}
333 excretion by thiazide diuretics).

334 *2.4 Hormones and hormone antagonists*

335 Chapter 48 “Agents Affecting Mineral Ion Homeostasis and Bone Turnover” provides a thorough
336 review of pharmacological agents used in treating and preventing mineral ion imbalances and bone
337 metabolism. The tables and figures are highly useful and summarize the main points of discussion,
338 particularly the drug summary table at the end of the chapter, which provides a quick reference for
339 understanding the pharmacological agents, their uses, and their clinical effects. This chapter will be useful
340 for both the medical student and seasoned healthcare professional in that in addition to discussing all of
341 the major pharmacological players involved in treating ion and bone diseases, it makes great attempts to
342 review and contextualize these treatment approaches by providing significant background information.
343 For example, this chapter contains a review of the basic hormonal control mechanisms involved in ion
344 homeostasis, target organs/systems, relevant bone cell physiology, and summary of the biology of
345 disorders of mineral homeostasis and bone. The chapter focuses on general concepts that have high
346 relevance in the clinical setting and are useful for directly understanding the underlying pharmacology.
347 This approach, while on the whole effective, does sometimes come at the expense of missing some
348 detailed but relevant information. For example, the chapter really does not discuss osteoclast function in
349 depth or bone resorption/remodeling effectively which would aid in the reader’s understanding of drugs
350 like bisphosphonates. This chapter also contains a decent summary discussing the integrated approach to
351 prevention and treatment of osteoporosis. This section does a more than adequate job of generally
352 summarizing the field with respect to the treatment strategies used for managing and preventing
353 osteoporosis.

354 *2.5 Gastrointestinal (GI) pharmacology*

355 Chapters 49 through 51 focus on gastrointestinal (GI) disorders. There are several positive aspects
356 to these chapters. First, the physiology and pathogenesis overview of each chapter and pharmacology of
357 each medication class is brief yet manages to remain quite detailed. The use of figures throughout allows
358 information to be more easily digested. Also, as a new text, this resource incorporates information on
359 recently approved agents, including medications like eluxadoline (Viberzi[®]) and vedolizumab (Entyvio[®]),
360 which naturally would be omitted by older resources. Finally, information on each drug and drug class
361 appears complete and accurate. Even adverse events recently identified by newer studies, like dementia
362 and chronic kidney disease for proton pump inhibitors (PPIs), are included.

363 On the other hand, there are several drawbacks as well. This section groups a large number of
364 topics into a small number of chapters, which could make readings challenging to assign to students. For
365 instance, to discuss a topic like *Helicobacter pylori* infection, one must first learn about PPIs early in
366 Chapter 49, then navigate through about two-thirds of the chapter before finally coming across a brief
367 discussion on managing the disorder.

368 The organization of Chapter 50, which covers motility disorders, emesis, and biliary and
369 pancreatic disease, is particularly hard to follow. The chapter begins by introducing antimotility agents
370 used in small populations and only available through limited access programs, if at all. Meanwhile, very
371 common motility disorders like diarrhea and constipation are buried throughout the lengthy chapter. Also,
372 the complications of cirrhosis, an important GI disorder, are mixed in only in short blurbs and in a
373 confusing manner throughout the chapter. A more complete discussion is vital and its absence is a
374 concerning flaw of this section.

375 Also, while it may be fitting to limit or omit information on medical interventions, such as
376 fundoplication surgery, there is limited coverage on nonpharmacologic interventions, which are some of
377 the most common and important recommendations pharmacists can make to patients. Additionally, some
378 aspects of these chapters assume a baseline understanding, which may not be beneficial for students who
379 do not possess this prior knowledge. For instance, terms like distal proctitis are left undefined, yet are
380 used freely when describing the therapeutic role of certain agents. Finally, compared to other resources,

381 this section uses fewer tables, making differences between medications or diseases more difficult to
382 establish.

383 Overall, chapters 49 to 51 allow individuals to build a strong foundation in pharmacologic
384 treatment of GI disorders by providing a great deal of information in a small number of chapters.
385 However, this section is not without its flaws. Improvement is needed with regard to organization,
386 coverage of cirrhosis, information on nonpharmacologic interventions, and the use of tables to present
387 data.

388 *2.6 Chemotherapy of infectious diseases*

389 Chapters 52, 56, 57 and 58 focus on infectious diseases. Chapter 52 is a general chapter focusing
390 on the general principles of antibacterial therapy. There are a few positive aspects to this chapter
391 including the step by step description of which antibiotic type (prophylactic, definitive, suppressive, etc.)
392 should be utilized in the ID process and detailed explanations of each type. The overview of the
393 pharmacokinetics of antibiotics is very detailed and the use of figures throughout the descriptions
394 provides visual explanations to better understand the information. The explanation on medication
395 resistance is very thorough and ensures that detailed information for resistance of each medication class
396 does not have to be discussed in each respective chapter.

397 Chapter 52, general principles of antimicrobial therapy, was very informative but does have some
398 disadvantages which make it somewhat difficult to follow. The pharmacokinetics section, though detailed
399 and useful, covers information beyond the need of healthcare providers. The descriptions of E_{max} and K_a ,
400 including equations, are explained well but are not necessary to fully describe the antibiotic classes. This
401 information is not useful when determining what antibiotic to utilize, nor does it explain how dosing is
402 affected based on these values. The explanation of time-dependent, concentration-dependent and
403 antibiotics with post-antibiotic effect are explained very well; however, a comprehensive table detailing
404 what medications fall into each category is not provided. Most other textbooks include a description of
405 what an infection entails and appropriate selection of antibiotics; however, this chapter jumps directly into
406 the pharmacokinetic information.

407 Chapters 56-58 discuss various antibacterial agents with descriptions of structure activity
408 relationships, mechanism of actions, antibacterial spectrum, pharmacokinetics and indications for each
409 medication within each respective class. The organization of the chapters has an excellent flow and is
410 consistent from class to class. In chapter 56, the discussion on medications used for urinary tract
411 infections is not consistent with the other medication classes; however, the information provided is very
412 thorough and does incorporate the same information provided by the other class of medications, just in a
413 different manner. Even though there are copious amounts of information provided on each respective
414 class and each medication within the class, the format and explanations are done in a very lay method
415 allowing non-healthcare providers to understand the material as well. The inclusion of historical facts
416 about certain medication classes improves the reading quality and provides background information on
417 either the class or the antibacterial spectrum of the class. In chapter 57, the inclusion of the carbenicillin
418 class is necessary to explain the class as a whole. Other texts will exclude these medications and only
419 discuss piperacillin/tazobactam; however, including the medications not available in the United States,
420 such as ticarcillin and mezlocillin, increase the credibility of piperacillin. Most texts have difficulty
421 explaining the cephalosporin generations; however, chapter 57 does an impeccable job detailing out
422 medications in each generation and relating it back to the antibacterial spectrum. The summary table at
423 the end of chapter 57 chapter 58 is all-inclusive and does a superb job at summarizing the chapter.

424 These chapters are very thorough and useful to a variety of healthcare providers; however, there
425 are a few limitations within these three chapters which provides information that is not needed or lacks
426 information in certain areas. In chapter 56, when discussing sulfonamides, several medications are
427 referenced which are not commonly used, including one which is not approved for use in the United
428 States. This excess information makes it more difficult to find the relevant information for medications
429 more commonly utilized. One major limitation within these three chapters is the lack of tables throughout
430 the chapter to simplify indications and dosing. All indications are separated into respective paragraphs
431 which makes it more difficult to follow, providing tables after each class highlighting the indication and
432 doses would allow readers to connect all medications within the class. It is understandable that not all new

433 medications could be included due to the publication process being lengthy; however, four medications
434 released within the last year are not included, two of which make a huge impact in practice. Delafloxacin
435 (Baxdela[®]) and the combination of meropenem and vabomere[®] were introduced within the
436 last year, but they have not warranted major changes; however, the combination of ceftazidime and
437 avibactam (Avycaz[®]) and the combination of ceftolozane and tazobactam (Zerbaxa[®]), medications
438 introduced specifically to fight off resistant pathogens such as carbapenemase-resistant enterobacteriaceae,
439 are essential for healthcare providers to know about due to increased resistance to other medications in
440 recent years.

441 Overall, these chapters allow healthcare providers to obtain the necessary pharmaceuticals
442 information needed to make decisions in patient care; however, improvements in formatting and the
443 inclusion of newer medications would benefit the text as a whole.

444 *2.7 Pharmacotherapy of Neoplastic Disease*

445 Chapter 65, “General Principles in the Pharmacotherapy of Cancer” is an excellent and
446 reasonably comprehensive background to cancer pharmacology. Strengths of this chapter include: (a)
447 distinguishing slower-growing cancers that have a smaller proportion of actively cycling tumor cells and
448 are thus less responsive to drugs that target the cell cycle; (b) stressing the importance of combinatorial
449 therapy, particularly combinations of molecularly targeted drugs and immunotherapy with more
450 generalized cytotoxic chemotherapy; and (c) a discussion of the various challenges of molecular testing to
451 determine those patients for whom specific targeted therapies would be most efficacious. With respect to
452 the last issue, the chapter not only discusses the issue of tumor heterogeneity but also properly cites
453 inherited genetic variation (and not just tumor-specific variation) as a factor affecting treatment response.
454 One criticism is, in the section on resistance, it is stated that the resistant cells pre-exist the treatment
455 which selects for these cells. While this no doubt occurs in the (vast) majority of cases (and the evidence
456 for this for kinase inhibitors is discussed in Chapter 67), it should be noted that resistant cells can occur
457 during treatment as a result of random mutations, unrelated to treatment, that may occur, particularly in
458 tumors exhibiting a hypermutable condition (e.g., MSI+). Also, the much more controversial issue of

459 adaptive mutation, which is starting to attract serious attention from a subset of researchers, could have at
460 least been mentioned in passing. For example, there has been a report of the possible role played by
461 adaptive mutation in the development of resistance to the androgen receptor antagonist bicalutamide in
462 prostate cancer cells.²⁸

463 Chapter 66 goes into great detail about several important classes of cytotoxic drugs, mostly those
464 that block cell division and/or promote apoptosis, but also the differentiating agent all-trans retinoic acid
465 (ATRA). Alkylating agents and platinum analogs come in for a particularly extensive review, and one
466 that does justice not only to mechanisms of action and therapeutic efficacy, but also the (often serious)
467 side effects of these agents. The chapter also makes an important distinction between bifunctional agents
468 and monofunctional methylating agents, which is helpful.

469 Chapter 67, “Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinases Inhibitors,
470 and Various Small Molecules” delves into a detailed examination of pathway-targeted therapies, centered
471 on small molecule inhibitors and monoclonal antibodies, two approaches that are contrasted with respect
472 to range of action and to their side effects (the small molecules tend to have both a greater range of
473 desirable activities as well as negative side effects). Similar to the examination of cytotoxic therapies in
474 the preceding chapter and to the more general introduction of chapter 65, attention is paid to issues of
475 mechanism of action, matching specific therapy to the appropriate type of cancer including genetic
476 variation of the cancer, preexisting inherited genetic variation of the patient that affects response, side
477 effects, and development of resistance. Also, combinatorial therapy is touched upon, an approach
478 particularly useful with the monoclonal antibodies. The sections on angiogenesis inhibitors and
479 immunotherapy (particularly the immune checkpoint inhibitors) was quite good, and this reviewer
480 positively notes the discussion of combinatorial immune checkpoint therapy targeting both cytotoxic T
481 lymphocyte-associated protein 4 (CTLA-4) and programmed death-1 (PD-1). There was some discussion
482 about how to overcome resistance; for example, resistance to the MEK inhibitor trametinib can be
483 overcome by combinatorial therapy with the BRAF inhibitor dabrafenib, and there is also discussion
484 about dealing with imatinib resistance. This is all significant; if anything, more on this topic can be

485 included; the same can be said about ameliorating side effects of these agents. There was some decent
486 discussion on this latter topic; particularly useful was the note about colony stimulating factors used to
487 deal with hematopoietic toxicity of many anti-cancer therapies. Certainly, an expanded analysis of such
488 topics is always welcomed. The section on histone deacetylase inhibitors was adequate, but there could
489 have been a discussion about butyrate, a fermentation product of dietary fiber, which is a histone
490 deacetylase inhibitor and one that may significantly mediate the anti-cancer properties of dietary fiber for
491 the colon. These topics could have been broached, which would have also allowed for a discussion of
492 how naturally occurring agents in food may exert preventive action against cancer. Although the book is
493 focusing on pharmacological therapy, the overlap between pharmacology and “medicinal food,” as well
494 as that between prevention and treatment, could have been productively addressed for the sake of
495 completeness. Chemoprevention is a legitimate topic in the field of cancer, both with respect to natural
496 products as well as, perhaps, other pharmacological agents. One issue that could have been included as
497 additional detailed discussion is the approach of inducing apoptosis through hyper-activation (rather than
498 inhibition) of signaling pathways the cancer cell is “addicted to.” There also could have been some
499 discussion of cutting-edge small molecules in clinical trial that target signaling pathways, such as ICG-
500 001-like compounds that inhibit CBP-mediated Wnt signaling. Further, by connecting issues such as
501 targeting signaling pathways, hyperactivating signaling pathways, and molecularly targeted drugs, one
502 could cite the finding that some histone deacetylase inhibitors can hyperactivate Wnt signaling to induced
503 apoptosis of colorectal cancer cells in culture, pointing to a possible novel therapeutic approach. That
504 underscores one weakness of these chapters: while they tend to give an excellent overview of existing
505 therapies, there is not much about possible novel future approaches.

506 Chapter 68 offers sound coverage on the role of hormone modulation for cancer therapeutics.
507 Two main approaches were addressed. First, there was discussion about glucocorticoids, which can not
508 only be used for anti-cancer treatment, but also to ameliorate side effects from other forms of cancer
509 therapy. Second, hormone-based therapy for breast and prostate cancer was addressed. Interestingly,
510 while anti-estrogen therapy is now important in breast cancer treatment, in the past, high doses of

511 estrogen were used for certain breast cancers to induce apoptosis. The chapter notes that it is necessary to
512 address the physiological type of breast cancer before commencing therapy, as some forms of the disease
513 are hormone-therapy resistant. The chapter also goes into detail about anti-androgen therapy for prostate
514 cancer, and this is well done, although analysis of quality-of-life issues would have strengthened the
515 discussion of pharmacology-based treatment options for this disease.

516 *2.8 Special systems pharmacology*

517 The dermatological and ocular pharmacology chapters have been greatly expanded compared to
518 the 12th edition of *GGPBT*. Five new agents (bentoquatam, coal tar, anthralin, brimonidine, and
519 propranolol) were added to the “miscellaneous agents” section and one agent was removed (podophyllin)
520 in the dermatological chapter compared to last edition. Both chapters have high quality colorful figures of
521 pathways and tables with details such as structural class and efficacy for each agent. Additionally, there is
522 a drug summary table at the end of the chapter with therapeutic uses, clinical pharmacology, and tips for
523 each agent to compliment the text.

524 The ocular chapter provides excellent explanation of the medications’ mechanisms of action and
525 describes which agent is preferred or which agent provides fewer side effects compared to an agent within
526 the same class. For example, brimonidine is less likely to cause ocular allergy and for that reason, it is
527 more commonly used. Although this information is presented throughout the chapter, it is not accessible
528 in one place. An algorithm highlighting what is first-line and second-line treatment for glaucoma in the
529 ocular chapter would have been beneficial to the reader.

530 When compared to Koda Kimble 10th edition,²⁹ the dermatological and ocular chapters in *GGPBT*
531 lack cases. It would have been helpful to have included case questions within the chapter, so the reader
532 can easily see how the pharmacological information is applicable to patients in practice. In comparison to
533 *KatBCP*,²³ the *GGPBT* dermatology chapter reviews more medications. However, the medication section
534 headlines are not as clearly defined and are presented in a less organized format. Within the sunscreen
535 portion in the dermatological chapter, it might have been desirable to have more details about each agent.
536 The chapters use only the generic name of medications. Since pharmacy students are expected to know

537 both brand and generic names for the NAPLEX and in practice, it would have been appropriate to use
538 both within the tables. In contrast, use of brand names would be less useful for medical students.
539 Additional information from a student perspective may be found in the Supplemental Appendix.

540

541 DISCUSSION

542 The quantitative and qualitative evaluation provided here is a substantial extension of prior
543 reports.^{1-8,12} Evaluating a large (currently > 1,440 pages) textbook¹⁻⁷ in just a few paragraphs, as is
544 common, loses some nuance and may do a disservice to the breadth of coverage for an interdisciplinary
545 and rapidly changing field. Overall, the editors and authors of _{GG}PBT should be recognized for assuming
546 such a large task as each new edition is a substantial and commendable achievement.

547 Approximately four out of every five _{GG}PBT authors were male. Unfortunately, this finding is
548 concurrent with a larger body of evidence.^{9, 10} For example, a widely used internal medicine textbook had
549 slightly fewer (18.6%) female authors.¹² The gender gap in _{GG}PBT authorship showed some
550 improvements relative to the 12th edition where eight out of nine contributors were male.⁸ At this rate,
551 _{GG}PBT may achieve gender parity when the sixteenth edition is published in 2039. We are not suggesting
552 that editors should recruit authors to achieve an arbitrary numerical representation. However, if the
553 expertise exists, as is evident in some pharmacotherapy textbooks,^{8,12} and the pool of authors
554 insufficiently reflects this diversity, then the policy that _{GG}PBT selects authors would merit
555 reconsideration.

556 Citations in _{GG}PBT were significantly less recent than those found in both _{Kat}BCP and _{DiP}PAPA.
557 Further, references were of similar age in _{Kat}BCP. The difference between sections with the most recent
558 and oldest citations was only 2.7 years versus over twice as large for _{DiP}PAPA (6.5) and _{GG}BCP (6.7).
559 Agents used for gastrointestinal disorders were most recent in _{GG}PBT and _{DiP}PAPA while drugs acting on
560 the nervous system were the most dated in _{GG}PBT and _{Kat}BCP. Possibly, the neuropharmacology sections
561 may change with further development of novel agents for Alzheimer's²⁹ and neuroendocrine
562 pharmacotherapies for obesity.³⁰

563 There is also substantial room for improvement in conflicts of interest transparency in _{GG}PBT.
564 With rare exceptions²¹, biomedical textbooks do not currently report on CoIs. Even in _{Dip}PAPA, which
565 discloses self-reported CoIs, four of the top ten highest compensated authors appeared to under-report
566 their disclosures which could be due to a narrow reporting time frame, a narrow definition of “relevant”
567 CoIs, or failing to provide the information to the editors. Editors may need to formalize responses to
568 inaccurate disclosure including reductions to the honorarium or exclusion from future editions. Primary
569 sources often employ the International Committee of Medical Journal Editors (ICMJE)³¹ form for
570 disclosure of potential CoIs where authors are instructed to be inclusive. More specifically, the
571 instructions specify “You should disclose interactions with ANY entity that could be considered broadly
572 relevant to the work. For example, if an article is about testing an epidermal growth factor receptor
573 (EGFR) antagonist in lung cancer, one should report all associations with entities pursuing diagnostic or
574 therapeutic strategies in cancer in general”. On the other hand, the ICMJE instructions might need to be
575 adjusted to incorporate the extended time-frame of textbooks where the same authors commonly
576 contribute to multiple editions over an extended period. Verification of self-reported disclosures with
577 ProPublica’s Dollars for Docs (_{pp}DD) and Medicaid Service’s Open Payments (_{CMS}OP) would be a trivial
578 task for publishing staff. Complete and accurate CoI disclosures will contribute to maintaining the highest
579 degree of trust that content is consistent with the principles of evidence based medicine²⁰ in subsequent
580 editions.

581 Narrative evaluations by content experts revealed several strengths but also some potential for
582 improvement. The neuropharmacology section missed an opportunity to at least begin to acquaint future
583 health care providers that terms in wide-spread use like “mood stabilizers”, “antipsychotics” and
584 “stimulants” are not informative and could be replaced by neuroscience-based nomenclature.²⁴ There is
585 also a need for more uniform avoidance of stigmatizing language.²⁷ In general, the chapters on neoplasia
586 are sound, and give a reasonably comprehensive overview on both traditional pharmacological therapies
587 as well as some of the newer, more cutting-edge approaches. There are some weaknesses, however. A
588 better understanding of the basic molecular biology would be helpful; in particular, this would strengthen

589 discussion about the development of resistance to theory, as well as how signaling pathways can be
590 modulated for therapeutic effect. Other areas of improvement would be an increased attention to
591 chemoprevention, novel future approaches, and quality of life issues concerning side effects of treatment.
592 More broadly, identification of which agents are not available in the United States at the time of
593 publication would benefit multiple sections.

594 Some caveats and limitations are noteworthy. First, the sex differences identified are consistent
595 with a broader pattern in academic medicine.^{8-10, 12} Future research should determine whether ethnic
596 minorities are similarly under-represented as biomedical textbook authors. Second, the CoI databases do
597 not report on non-financial CoIs or the financial relationships of non-physicians (i.e. half of _{GG}PBT
598 authors). Therefore, the three million received by authors from pharmaceutical companies is likely an
599 underestimate. The presence of potential CoI, although appreciable, does not necessarily mean that
600 content was impacted in any way. Third, the textbook citation differences in Figure 1A would be less
601 pronounced if _{GG}PBT were published slightly (one year) earlier. Therefore, the findings within each
602 textbook (Figures 1B, 1C, 1D) may be more meaningful. On the other-hand, while the findings in Figure
603 1A were hypothesized *a priori*, the results in Figure 1B-D were not and may be susceptible to Type I
604 errors. Fourth, although the narrative reviewers came from diverse fields and had substantial experience
605 as educators, health care providers, and biomedical scientists, collectively, we are a far less distinguished
606 group than the esteemed authors of _{GG}PBT. There is some subjectivity underlying expert opinion and it is
607 likely that others may have identified somewhat different strengths and limitations in _{GG}PBT content.

608

609 CONCLUSION

610 This report identifies many strengths of the 13th edition of _{GG}PBT but also some areas for improvement
611 including greater diversity of authors, heightened transparency of conflict of interest disclosures, and
612 improved recency of citations in select areas.

613

614 ACKNOWLEDGEMENTS AND DISCLOSURES

615 This endeavor was completed using software provided by the Husson University School of Pharmacy and
616 the National Institute of Environmental Health Sciences (T32 ES007060-31A1). BJP is supported by the
617 Center of Excellence, Health Resources Services Administration (D34HP31025) and Pfizer. DYK is
618 currently employed with a biotechnology company. John Szarek, PhD provided feedback on an earlier
619 version. This report is based on the analysis of the authors and does not reflect the opinions of our
620 respective institutions.

621

622 REFERENCES

- 623 1. Dameshek W. The Pharmacological Basis of Therapeutics. Yale J Biol Med. 1941; 13(4): 558–
624 559.
- 625 2. B.L.D. The Pharmacological Basis of Therapeutics, 2nd. Ed J Am Dent Soc Anesthesiol. 1958;
626 5(3): 30–31.
- 627 3. Lowell RJ. The Pharmaceutical Basis of Therapeutics, 4th ed. Anesth Prog. 1971; 18(1): 19.
- 628 4. R.G.W. The Pharmacological Basis of Therapeutics. Ulster Med J. 1981; 50(1): 68.
- 629 5. Hastings RC, Long GW, Goodman and Gilman's The Pharmacological Basis of Therapeutics.
630 JAMA -J Am Med Assoc. 1996; 276: 999-1000.
- 631 6. Rosenberg M. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th Edition,
632 Anesth Prog. 2003; 50(4): 190–191.
- 633 7. Casavant MJ. Goodman and Gilman's Pharmacological Basis of Therapeutics. JAMA-J Am Med
634 Assoc. 2002; 288: 2052.
- 635 8. Piper BJ, Telku HM, Lambert DA. A quantitative analysis of undisclosed conflicts of interest in
636 pharmacology textbooks. PLoS One 2015; 10(7): e0133261.
- 637 9. Filardo G, da Graca B, Sass DM, Pollock BD, Smith EB, Martinez MA. Trends and comparison
638 of female first authorship in high impact medical journals: observational study (1994-2014).
639 BMJ-Brit Med J. 2016; 352: i847.
- 640 10. Asghar M, Usman MS, Aibani R, Ansari HT, Siddiqi TJ, Fatima K, Khan MS, Figueredo VM.
641 Sex differences in authorship of academic cardiology literature over the last 2 decades. J Am Coll
642 Cardiol. 2018; 72(6):681-685.
- 643 11. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, L. Posey LM. Pharmacotherapy: A
644 Pathophysiologic Approach. 10th ed. New-York: McGraw-Hill, 2017.
- 645 12. Piper BJ, Lambert DA, Keefe RC, Smukler PU, Selemon NA, Duperry ZR. Undisclosed conflicts
646 of interest among biomedical textbook authors. AJOB Empirical Bioethics 2018; 9:59-68.

- 647 13. National Academy of Medicine. Conflict of Interest in Medical Research, Education, and
648 Practice. Washington, DC: National Academies Press. 2009.
- 649 14. Drazen JM, de Leeuw PW, Laine C, Mulrow C, DeAngelis CD, Frizelle FA, et al. Toward more
650 uniform conflict disclosures--the updated ICMJE conflict of interest reporting form. *New Engl J*
651 *Med.* 2010; 363(2):188-9.
- 652 15. Ivanov A, Kaczowska BA, Khan SA, Ho J, Tavakol M, Prasad A, Bhumireddy G, et al. Review
653 and analysis of publication trends over three decades in three high impact medicine journals.
654 *PLoS One.* 2017; 12(1): e0170056.
- 655 16. Carlat DJ, Fagrelus T, Ramachandran R, Ross JS, Bergh S. The updated AMSA scorecard of
656 conflict of interest policies: A survey of U.S. medical schools. *BMC Med Educ. Medical*
657 *Education* 2016; 16:202.
- 658 17. Accreditation Council for Continuing Medical Education. ACCME standards for commercial
659 support: standards to ensure the independence of CME activities. Chicago, IL: ACCME. 2007.
660 [http://www.accme.org/dir_docs/doc_upload/68b2902a-fb73-44d1-8725-](http://www.accme.org/dir_docs/doc_upload/68b2902a-fb73-44d1-8725-80a1504e520c_uploaddocument.pdf)
661 [80a1504e520c_uploaddocument.pdf](http://www.accme.org/dir_docs/doc_upload/68b2902a-fb73-44d1-8725-80a1504e520c_uploaddocument.pdf). Accessed August 8, 2018.
- 662 18. Chopra AC, Tilberry SS, Sternat KE, Chung DY, Nichols SD, Piper BJ. Quantification of
663 conflicts of interest in an online point-of-care clinical support website. *Science & Engineering*
664 *Ethics*, in review.
- 665 19. Bero L. Industry sponsorship and research outcome: A Cochrane Review. *JAMA Intern Med.*
666 2013; 173:580-581.
- 667 20. Ngo-Metzger Q, Moyer V, Grossman D, Ebell M, Woo M, Miller T, et al. Conflicts of interest in
668 clinical guidelines: Update of U.S. Preventive Services Task Force policies and procedures. *Am J*
669 *Prev Med.* 2018; 54(1S1): S70-S80.
- 670 21. Stahl SM. *Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical*
671 *Applications.* 4th ed. Cambridge, UK: Cambridge University Press. 2013.


- 672 22. Brunton LL, Hilal-Dandan RH, Knollman BC. Goodman & Gilman's: The pharmaceutical basis
673 of therapeutics. 13th ed. New York, NY: McGraw-Hill. 2018.
- 674 23. Katzung BG. eds. Basic & Clinical Pharmacology. 14th ed. New York, NY: McGraw-Hill. 2018.
675 <http://accesspharmacy.mhmedical.com/content.aspx?bookid=2249§ionid=175215158>.
676 Accessed January 13, 2019.
- 677 24. Nutt DJ, & Blier P. Neuroscience-based Nomenclature (NbN) for Journal of
678 Psychopharmacology. J Psychopharmacol. 2016; 30:413-415
- 679 25. Piper BJ, Shah DT, Simoyan OM, McCall KL, Nichols SD. Trends in medical use of opioids in
680 the U.S., 2006-2016. Am J Prev Med. 2018; 54(5): 652-660.
- 681 26. Pergolizzi JV, LeQuang JA, Berger GK, Raffa RB. The basic pharmacology of opioids informs
682 the opioid discourse about misuse and abuse: A review. Pain Ther. 2017; 6:1-16.
- 683 27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed.
684 Arlington, VA: American Psychiatric Publishing. 2013.
- 685 28. Hara T, Kuono J, Nakamura K, Kusaka M, Yamaoka M. Possible role of adaptive mutation in
686 resistance to antiandrogen in prostate cancer cells. The Prostate 2005; 65: 268-275.
- 687 29. Alldredge BK, Corelli RL, Ernst ME, Guglielmo BJ, Jacobson PA, Kradjan WA. Koda-Kimble
688 and Young's applied therapeutics: The clinical use of drugs. 10th ed. Philadelphia, Pennsylvania:
689 Lippincott.
- 690 30. Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K. Alzheimer's disease drug development
691 pipeline: 2017. Alzheimers Dement. 2017; 3:367-384.
- 692 31. Srivastava G, Apovian C. Future pharmacotherapy for obesity: New anti-obesity drugs on the
693 horizon. Curr Obes Rep. 2018; 7(2):147-161. doi: 10.1007/s13679-018-0300-4.
- 694 32. International Committee of Medical Journal Editors. The ICMJE Conflict of Interest form.
695 Accessed 1/13/19 at: <http://www.icmje.org/conflicts-of-interest/>
696

- 697 33. Katsila, T., Konstantinou E, Lavda I, Malakis H, Papantoni I, Skondra L, Patrinos GP.
698 Pharmacometabolomics-aided pharmacogenomics in autoimmune disease. EBioMedicine 2016; 5
699 : 40-45.
- 700 34. Tabor, H. K., Neil J. Risch, Myers RM. Candidate-gene approaches for studying complex genetic
701 traits: practical considerations. Nature Reviews Genetics 2002; 3.5: 391.
702
703
704
705
706


707 **Figure Caption**

708

709 **Figure 1.** Citation age (\pm SEM) for *Goodman and Gilman's Pharmacological Basis of Therapeutics*
710 (_{GG}PBT, 13th edition, 2018) relative to *Katzung's Basic and Clinical Pharmacology* (_{Kat}BCP, 14th edition,
711 2018) and *DiPiro's Pharmacotherapy: A Pathophysiologic Approach* (_{DiP}PAPA, 10th edition, 2017, A. * p
712 $< .01$ versus _{GG}PBT, [#] $p < .0005$ versus _{Kat}BCP). Age by section of _{GG}PBT (B, ⁿ $p < .0005$ versus
713 Neuropharmacology; ^g $p < .0005$ versus Gastrointestinal), _{Kat}BCP (C, ^a $p < .05$ versus Autonomic, ^b $p < .05$
714 versus Basic Principles, ^c $p < .05$ versus Central Nervous System (CNS). PRC: Pulmonary, Renal,
715 Cardiovascular; BIG: Blood, Inflammation, Gout) and _{DiP}PAPA (D, $p < .01$ versus Gastrointestinal
716 Disorders, and Gynecologic and Obstetric Disorders).



718 **Supplementary Figure 1.** Scatterplot depicting the similarity in undisclosed potential conflicts of interest
719 among Goodman and Gilman's *The Pharmacological Basis of Therapeutics* (GGPBT) authors as reported
720 by ProPublica's Dollars for Docs (ppDD) and the Center for Medicare and Medicaid Service's (CMS)
721 Open Payments. $R^2 = .9978$, $p < .0001$. Two authors (e.g. oncologist CI = \$185,223 in DD vs \$209,943 in
722 OP) had more payments reported by Open Payments.



723
724
725
726

Supplemental Table 1. Comparison of self-reported and mandated reporting of conflicts of interest among the ten highest compensated authors of DiPiro's Pharmacotherapy: A Pathophysiologic Approach, 2017. ^Nname not listed in the disclosures provided by Access Pharmacy 12/10/18.

<u>Author: Chapter</u>	<u>Self-Report</u>	<u>ProPublica's Dollars for Docs 2013 to 2016</u>
KD: Parkinson Disease	not reported ⁿ	\$729,695, \$349,614 for Parkinson Disease treatments (Apokyn: \$132,702, Azilect = \$111,326, Duopa: \$34,934, Deep Brain Stimulation: \$1,200)
JWW: Status Epilepticus	"none"	\$644,986, \$533,633 for anti-epileptic drugs (Fycompa: \$235,680, Oxtellar: \$78,942, Sabril: \$62,700, Onfi: \$58,630, Banzel: \$49,082, Qudexy: \$24,122, Aptiom: \$11,144, Trokendi: \$10,082, Vimpat: \$3,521)
ESR: Urinary Incontinence	"Consultant: Allergan, Astellas Pharma, and Ferring Pharmaceuticals"	\$227,510, \$131,600 for Urinary Incontinence treatments (Botox/Allergan: \$78,260, Myrbetriq/Astellas: \$25,584, Toviaz/Pfizer: \$10,815, Vesicare/Astellas: \$8,790, Interstim/Medtronic: \$8,151)
AM: Multiple Sclerosis	not reported ⁿ	\$99,634, \$69,907 for Multiple Sclerosis treatments (H.P. Acthar: \$16,034, Copaxone: 11,591, Plegrity: \$10,122, Lemtrada: \$8,698, Tysabari: \$8,630, Aubagio: \$6,086; Alemtuzumab: \$5,601, Bateseron: \$3,145)
SSCR: Gastroesophageal Reflux	not reported ⁿ	\$53,588, \$0 for Gastroesophageal Reflux drugs
DCH: Stroke	not reported ⁿ	\$14,762, \$125 for Thrombectomy device
DJL: Pulmonary Arterial Hypertension	"none"	\$13,573, \$10,817 for Pulmonary Arterial Hypertension treatments (Letaris: \$4,142 Orenitram, \$2,251, Tyvaso: 2,219, Remodulin: \$2,205)
JP: Pulmonary Function Testing	"none"	\$2,716, \$0 for Pulmonary Function Testing
MSH: Drug Induced Pulmonary Disease	"none"	\$2,045, \$0 for Drug Induced Pulmonary Disease
JMC: Colorectal Cancer	"none"	\$1,824, \$0 for Colorectal Cancer treatments

Supplementary Appendix A. Evaluation of two master's students.

#1: The new edition of *Goodman and Gilman's Pharmacological Basis of Therapeutics* (GGPBT) seeks to explain the concepts of pharmacology beginning with the basics and continuing through some of the practical applications used in many hospitals today. The organization of the text is superb and allows for easy comprehension. After the basics are covered, the physiological systems and their drug targets are neatly categorized so as to help the reader understand the interactions between the biological system, the underlying disease, and appropriate medication. After each of the tissue or system specific maladies are covered, the text delves into more broad illnesses and their treatments in the infectious disease and chemotherapy sections.

The writing in the text is clear and easy to understand. Each disease is well defined, and the text makes good use of diagrams and figures to explain the mechanisms behind the illness. After elucidating the cause of the problem, the text explains the mechanisms behind each potential treatment, and clearly summarizes their advantages and risks in a table. Any unusual or dangerous interactions of a drug are sufficiently explained, and the precautions to using such a medication are always described.

#2 The 13th edition of *Goodman and Gilman's Pharmacological Basis of Therapeutics* (GGPBT) made the learning and interpretation of pharmacology easier for the reader. The way the content is organized, the reader is better able to pick out important ideas from the support given on each topic. This provides a good outline for studying the material required by any specific course using this textbook.

The order of the text overall offers a lot of information at the beginning, and towards the end there are applications of the reader's knowledge to the treatment of specific diseases and uses for some of the drugs. The text also provides an explanation for physiological processes before explaining the drugs that affect them, which allows the reader to have a better understanding of the significance and action of the drug. Each chapter is formulated so that the material is interesting, and difficult subjects are explained well so that the reader is not lost in the details. There is sufficient support given for the content, so the reader can apply what they are learning to other outside sources and ideas. Clear and legible figures and tables are placed throughout the text in order for the reader to visualize the content in a different form. Explaining the image well within the text provides a good flow that allows the student to understand the topic better. The drug summary tables that are provided are informational and concise which offers the reader a good summary resource. The antipsychotic molindone is listed as "not available in the US" in Table 16-2 but was listed in October 2018 as available¹. An online textbook can be regularly updated.

Although the text does engage the reader, GGPBT does not provide sufficient critical thinking points throughout the text. There are no problem-solving opportunities for each topic, which limits the application and testing of material. The student would need to purchase yet another book for this.²

¹<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1275e92f-9573-4d0c-8e77-1c9ac47696d2>

²Rollins DE, et al. Workbook and casebook for Goodman & Gilman's The Pharmacological Basis of Therapeutics, 2016, McGraw Hill.